Express Pharma

Novartis completes series of transactions with GSK

139

Acquires certain oncology products and pipeline compounds from GSK

Novartis has completed a series of transactions with GlaxoSmithKline (GSK), including the acquisition of certain oncology products and pipeline compounds from GSK, the creation of a world-leading consumer healthcare business through a joint venture that combines the two companies’ consumer divisions, and the divestiture of the Novartis non-influenza Vaccines business to GSK. The transactions were announced in April 2014 as part of the Novartis global portfolio transformation.

“The completion of the GSK transactions focuses Novartis, and further establishes our leading positions in key growing business segments,” said Joseph Jimenez, Chief Executive Officer, Novartis. “We expect this evolution of our strategy to improve margin performance and position us well to meet future changes in the healthcare industry.”

Since the end of 2013, Novartis has engaged in a series of transactions to sharpen the company’s focus on three core business segments with global scale: innovative pharmaceuticals, eye care and generics.

Novartis Oncology now manages a portfolio of 22 oncology and hematology medicines to treat more than 25 conditions worldwide. Newly-acquired therapies i